Evidence map›Paper›PMID 42729713›Full record

ReviewFrontiers in pediatrics2026

Herpes zoster frequency and severity in immunocompromised pediatric populations: a structured narrative review.

Chris Simpson, Emma Viscidi, Adva Gadoth

Abstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chris SimpsonEpidemiologic Research & Methods LLC, Atlanta, GA, United States.
Emma ViscidiModerna Inc., Cambridge, MA, United States.
Adva GadothModerna Inc., Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While herpes zoster (HZ) is known to disproportionately affect people with immunocompromising (IC) conditions, reviews of the frequency and severity of HZ in these conditions have so far been limited to adults. Methods: For this narrative review, we conducted a literature search to identify studies describing HZ frequency in pediatric cohorts with IC conditions including hematopoietic cell transplant, cancer, solid organ transplant, human immunodeficiency virus (HIV), or autoimmune disease commonly treated with immunosuppressants. We also extracted information on HZ complications, when available. Results: Forty-one articles published between 1997 and 2024 from 22 countries were identified. Thirty-four reported risk (cumulative incidence) and 21 reported incidence rates of HZ. The frequency of HZ was elevated in all IC conditions studied compared to that in the general pediatric population. Risk of HZ was particularly high among children receiving HCT (median cumulative incidence: 18%; median follow-up: two years) and children with systemic lupus erythematosus (SLE) (median cumulative incidence: 26%; median follow-up: six years). Children with inflammatory bowel disease had HZ incidence rates approximately three times that of controls. Across all IC conditions, postherpetic neuralgia was less common and resolved faster than in immunocompromised adults, but acute complications were no less common. Varicella vaccination was associated with lower HZ risk in all studies that reported on this intervention. Conclusions: Children with IC and autoimmune conditions, particularly HCT and SLE, develop HZ more frequently and are more likely to experience HZ complications than other children. Varicella vaccination appears to reduce these risks.

Indexed as

autoimmuneepidemiologyherpes zoster (HZ)immunocompromisedpediatricsvaricella and herpes zostervaricella vaccination

Identifiers

PMID42729713
PMCPMC13563003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.